

Patent Information Initiative for Medicines

Pat-INFORMED

December 8, 2021

33rd Session of the Standing Committee on the Law of Patents

Charles Randolph (Charles.Randolph@WIPO.INT)

Head, NGO & Industry Relations

What is Pat-INFORMED?

- The **Patent Information Initiative for Medicines**, (Pat-INFORMED) is a search engine to help pharmaceutical procurement agencies determine the patent status of a medicine.
- It **facilitates access to and availability of pharmaceutical patent information** to inform procurement decisions.
- Pat-INFORMED is a partnership among WIPO, IFPMA and 20 global pharma companies.

What Pat-INFORMED is NOT?

- A one-stop shop listing all information relevant to procurement.
- A linkage system (listing in Pat-INFORMED has no legal implication).
- A freedom-to-operate analysis tool.

Why did we create Pat-INFORMED?

- Greater transparency of patent information on medicines.
- “WIPO Development Agenda Goal 31:”... Better access to publicly available patent information...
- UN Sustainable Development Goals:
 - Goal 3 Promote health and well-being
 - Goal 9 Foster innovation
 - Goal 17 Strengthen implementation through partnerships

Which therapeutic areas does Pat-INFORMED cover?

HIV/
AIDS

Cardiovascular
diseases

Diabetes

Hepatitis
C

Oncology

Respiratory
conditions



All products on the WHO EML that are not within these therapy areas

→ Companies are now populating the database to cover all small-molecules therapeutic areas.

Who can use Pat-INFORMED?



- The Pat-INFORMED database is accessible to everybody.




- The follow-on enquiry facility is limited to national and international procurement agencies. Information received is not confidential.

What's in Pat-INFORMED?


- 20 Companies
- 232 INNs (169 at launch)
- 660 Patent Families (600 at launch)
- 21,492 Patents (14,000 at launch)


2021 Visits

Visits Overview (in 2021)

 **8,539** visits, **5,813** unique visitors


 **1 min 12s** average visit duration


 **82%** visits have bounced (left the website after one page)


 **1.3** actions (page views, downloads, outlinks and internal site searches) per visit


 **0.19s** average generation time


 **0 M** Bytes transferred overall

 **10,684** pageviews, **8,534** unique pageviews


 **0** total searches on your website, **0** unique keywords

 **94** downloads, **87** unique downloads






























 **46** outlinks, **45** unique outlinks

 **14** max actions in one visit

2021 Visits – Geographic Distribution



2021 Visits – by place

COUNTRY	▼ VISITS	COUNTRY	▼ VISITS
 India	1,535	 Mexico	121
 United States	1,055	 Netherlands	106
 Russia	542	 Malaysia	102
 United Kingdom	399	 Singapore	102
 Switzerland	362	 Argentina	95
 Japan	322	 Hong Kong SAR China	89
 China	275	 Vietnam	87
 Spain	256	 Chile	84
 Turkey	226	 Australia	82
 Indonesia	211	 Ukraine	79
 Germany	199	 South Korea	73
 Brazil	181	 Latvia	69
 Italy	168	 Algeria	66
 France	163	 Belarus	64
 Canada	129		

Thank you



Patent Information Initiative for Medicines Pat-INFORMED

Guilherme Cintra
Director, Innovation Policy (IFPMA)

Pat-INFORMED: Key functionalities

DATABASE

DATABASE that helps pharmaceutical procurement experts around the world access patent information by country.

FACILITY TO REQUEST

It offers procurement agencies and experts the **FACILITY TO REQUEST** additional information directly from the patent holders.

The screenshot shows the Pat-INFORMED website interface. At the top, there is a teal header with the text "PAT-INFORMED Patent Information Initiative for Medicines" on the left, navigation links "My account | Terms of use | Contact us" in the center, and the WIPO logo with "Hosted by WIPO" on the right. Below the header, the main content area features a white box titled "PAT-INFORMED DATABASE" with the subtitle "The gateway to medicine patent information". The text inside the box describes the database's search capabilities and provides links to PATENTSCOPE. To the right of the text are the WIPO and IFPMA logos. Below the white box is a search bar with the placeholder text "Search pharmaceutical patents by INN - Ex : vilanterol trifenate" and a search icon. To the right of the search bar is a "Country" dropdown menu. At the bottom of the search bar, there is a link "Display all INNs". The footer of the page includes the text "WIPO FOR OFFICIAL USE ONLY" on the left, "ORGANIZATION - PROPE" on the right, and the IFPMA logo on the far right.

PAT-INFORMED DATABASE

The gateway to medicine patent information

Search the Pat-INFORMED database by entering a medicine's INN (International Non-Proprietary Name) to obtain relevant information about its patent status in a particular country. Pat-INFORMED also provides a facility for procurement agencies to make follow-up inquiries directly with participating companies. The database also links to available information on WIPO's own global database, PATENTSCOPE.



Search pharmaceutical patents by INN - Ex : erlotinib hydrochloride



Country 

[Discover all INNs](#)

Search pharmaceutical patents by INN - Ex : erlotinib hydrochloride



Country ▾

Display all 200a

INN	Participant	Patents
Fluticasone Propionate, Salmeterol Xinafoate		AEROSOL CONTAINER FOR FORMULATIONS OF SALMETEROL XINAFOATE
Fosamprenavir Calcium		CALCIUM (3S) TETRAHYDRO-3-FURANYL(1S,2R)-3-[[[4-AMINOPHENYL] SULFONYL] (ISOBUTYL) AMINO] -1-BENZYL-2-(PHOSPHONOXY) PROPYL CARBAMATE
Dasatinib		FORMULATIONS OF A SRC/ABL INHIBITOR
Erlotinib Hydrochloride		STABLE POLYMORPH OF N-(3-ETHYNYLPHENYL AMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
Vemurafenib		COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS
Lenvatinib Mesilate		QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION
Azilsartan Medoxomil, Chlortalidone		SOLID PHARMACEUTICAL COMPOSITION
Enzalutamide		Treatment Of Hyperproliferative Disorders With Diarylhydantoin Compounds
Efavirenz		CRYSTALLINE EFAVIRENZ
Umeclidinium Bromide, Vilanterol Trifenatate		PHENETHANGLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
Fluticasone Furoate		COUNTER FOR USE WITH A MEDICAMENT DISPENSER
Abacavir Sulfate		CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN TREATING VIRAL INFECTIONS
		POLYCYCLIC CARBAMOYLPIRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

Sunitinib Malate Country ▾

(Sunitinib Malate)

INN	Participant	Patents
Sunitinib Malate		<p>CRYSTALS INCLUDING A MALIC ACID SALT OF N-[2-(DIETHYLAMINO)ETHYL]-5-[5-FLUORO-2-OXO-3H-INDOLE-3-YLIDENE] METHYL]-2, 4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, PROCESSES FOR ITS</p> <p>PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS</p>

🔍 **Discover**

PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

Participant: 

In order to contact Pfizer about this patent, you need to [log in](#) or [create an account](#).

The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I); and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

[Information on the company's policy that may be related to the product](#)

DISCLAIMER: PAT-INFORMED is not intended as a replacement for a freedom-to-operate analysis, is not free of errors, and should not be relied upon as a comprehensive inventory of patent information. Pending applications are not listed, and in certain cases licensing arrangements may prevent Participants from listing patents. Use of PAT-INFORMED is subject to the [Text of Use and Guidelines](#).

<p>Jurisdiction CD - Congo, The Democratic Republic of the</p> <p>Filing date 2002/08/24 (18 years ago)</p> <p>Grant date 2008/11/11 (9 years ago)</p> <p>Grant number 400/2010</p> <p>(Country not covered by PATENTSCOPE.)</p>	<p>Jurisdiction CH - Switzerland</p> <p>Publication number 1258792</p> <p>Publication date 2002/11/13 (16 years ago)</p> <p>Filing date 2001/02/15 (18 years ago)</p> <p>Grant date 2007/08/08 (11 years ago)</p> <p>Grant number 1258792</p> <p>(Country not covered by PATENTSCOPE.)</p>
<p>Jurisdiction CL - Chile</p> <p>Filing date 2002/02/15 (18 years ago)</p> <p>Grant date 2008/08/09 (10 years ago)</p> <p>Grant number 43.488</p>	<p>Jurisdiction CN - China</p> <p>Publication number 1439005</p> <p>Publication date 2003/08/27 (16 years ago)</p> <p>Filing date 2001/02/15 (18 years ago)</p> <p>Grant date 2007/08/01 (11 years ago)</p> <p>Grant number ZL01807289.8</p> <p>Open in PATENTSCOPE</p>
<p>Jurisdiction CO - Colombia</p> <p>Publication number 528</p> <p>Publication date 2003/05/30 (15 years ago)</p> <p>Filing date 2001/02/15 (18 years ago)</p> <p>Grant date 2020/09/30 (8 years ago)</p> <p>Grant number 28162</p>	<p>Jurisdiction CY - Cyprus</p> <p>Publication number 1258792</p> <p>Publication date 2002/11/13 (16 years ago)</p> <p>Filing date 2001/02/15 (18 years ago)</p> <p>Grant date 2007/08/08 (11 years ago)</p> <p>Grant number CY108032</p>

PAT-INFORMED

WIPO

Search: Suntrib Malate

Country: [Dropdown]

Participant: Pfizer

PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

Participant: Pfizer

In order to contact Pfizer about this patent, you need to [log in](#) or [create an account](#).

The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I) and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Publication: CN - China
 Publication number: 1439005
 Publication date: 2003/08/27 (15 years ago)
 Filing date: 2001/02/15 (18 years ago)
 Grant date: 2007/08/01 (11 years ago)
 Grant number: ZL01807269.0
[Open in PATENTSCOPE](#)

Publication: CY - Cyprus
 Publication number: 1255752
 (Country not covered by PATENTSCOPE.)

Publication: CO - Colombia
 Publication number: 2812
 Publication date: 2003/08/27 (15 years ago)
 Filing date: 2001/02/15 (18 years ago)
 Grant date: 2007/08/01 (11 years ago)
 Grant number: ZL01807269.0

Publication: CN - China
 Publication number: 1439005
 Publication date: 2003/08/27 (15 years ago)
 Filing date: 2001/02/15 (18 years ago)
 Grant date: 2007/08/01 (11 years ago)
 Grant number: ZL01807269.0
[Open in PATENTSCOPE](#)

Publication: CY - Cyprus
 Publication number: 1255752
 (Country not covered by PATENTSCOPE.)



Machine translation

1. (CN1439005) Pyrrole substituted 2-indolinone protein kinase inhibitors

National Biblio. Data Description Claims Drawings Documents

PermaLink

Application Number: 01807269.0 **Application Date:** 15.02.2001
Publication Number: 1439005 **Publication Date:** 27.08.2003
Grant Number: 1329390 **Grant Date:** 01.08.2007
Publication Kind : C
Prior PCT appl.: Application Number:PCTUS2001004813 ; Publication Number:2001060814 Click to see the data

IPC:	C07D 403/06 A61K 31/404 A61P 43/00 C07D 403/14 C07D 401/14	CPC:	C07D 233/56 C07D 207/33 C07D 209/44 C07D 231/12 C07D 249/08 C07D 401/12 C07D 401/14 C07D 403/06 C07D 403/12 C07D 403/14
-------------	--	-------------	--

Applicants: Sugen, Inc.
苏根公司
法马西亚及厄普约翰公司

Inventors: Tang Peng-Cho
唐彭出
Todd Miller
托德·米勒
Li Xiaoyuan
李小元
孙利
魏忠臣
萨赫扎德·舍拉齐安
梁崇新

1. (CN1439005) Pyrrole substituted 2-indol...

Machine translation

- Wipo Translate
- Google Translate
- Bing/Microsoft Translate
- Baidu Translate

Arabic
German
English
Spanish
French
Japanese
Korean
Portuguese
Russian
Chinese

吡咯取代的2-二氢吲哚酮蛋白激酶抑制剂

交叉参考信息

本申请根据35 U.S.C. 119(e) 提出对2000年2月15日提交的美国 专利临时申请60/120000、2000年7月6日提交的60/216,422和2000 年10月27日提交的60/243,532的优先权，它们的公 告在本 申请中作为参考。

发明背景

发明领域

本发明涉及某些调节蛋白激酶 (“PK”) 活性的3-吡咯取代的 2-二氢吲哚酮。本发明化合物 因此可用于治疗与PK活性反常有关的 疾病。还公开了含这些化合物的药物组合物，使用含这些化 合物的药 物组合物治疗疾病的方法及它们的制备方法。

技术状况

以下只作为背景信息提供，不认为是本发明的先有技术。

PK是对蛋白质的酪氨酸、丝氨酸和苏氨酸残基上的羟基的磷酸化 起催化作用的酶。这种看 起来简单的活性的后果惊人：细胞生长、分 化和增殖，即，实际上细胞生命的所有方面都以这样或 那样的方式与 PK活性有关。另外，PK活性反常与许多疾病有关，包括相对无生命 威胁的疾病，如牛 皮癣，到极其致命的疾病，例如成胶质细胞瘤(脑 癌)。

PK可以方便地分成两类：蛋白酪氨酸激酶(PTK)和丝氨酸-苏 氨酸激酶(STK)。

PTK活性的一个主要方面是它们与生长因子受体有关。生长因子 受体是细胞表面蛋白质。当 与生长因子配体结合时，生长因子受体被 转化成活性形式，它与细胞膜内表面上的蛋白质相互作 用。这导致受 体和其它蛋白质的酪氨酸残基上的磷酸化，并导致细胞内部形成与多 种胞质信号分子 的复合物，这反过来又影响许多种细胞相应，例如细 胞分裂(增殖)、细胞分化、细胞生长、代谢作 用对胞外微环境的表 达等。更完全的讨论请参阅Schlessinger和Ullrich, *Neuron*, 9: 303- 391(1992)，该文包括所有附图都象本申请中充分陈述的一样，被引 用作为参考。

具有PTK活性的生长因子受体被称作受体酪氨酸激酶 (“RTK”)。 它们包含一大族具有不同



1. (CN1439005) Pyrrole substituted 2-indolinone protein kinase inhibitors

National Biblio. Data Description Claims Drawings Documents

Wipo Translate [powered by Marian] zhen ...

[Continue translation] ...

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Pyrrole-substituted 2-dihydroindol-one protein kinase inhibitor

Cross-reference information

The application is 35 U/S/C119. (e) and claims the benefit of US provisional application no. 60/182,710 filed feb. 15, 2000., 60/216 filed on jul. 6, 2000, and 60/243,532 filed oct. 27, 2000, and their disclosures are all incorporated herein by reference.

Background

Field of the invention

The invention relates to certain regulatory protein kinases ("PK") and the active 3-pyrrole substituted 2-dihydroindol-one compound can be used for treating diseases related to PK activity abnormality. Also disclosed is a pharmaceutical composition containing these compounds., the invention relates to a method for treating diseases by using a pharmaceutical composition containing the compounds and a preparation method of the pharmaceutical composition

Technical condition

The following is only provided as background information and is not considered to be a prior art of the present invention

Pk is tyrosine for protein, serine and the hydroxyl on the threonine residue, so that the result of the enzyme with simple activity is surprising.: cell growth, differentiation and proliferation, in this way, all aspects of the cell life are related to the pk activity in such a way that the cell life is in the same or similar manner. In addition, the pk activity abnormality is related to a number of diseases, including a disease that is relatively free of life threats, such as psoriasis, to extremely fatal diseases, such as glioblastoma (brain cancer)

The pk can be conveniently classified into two types of protein tyrosine kinase (pTIF) and serine-threonine kinase (sThe)

One major aspect of PTK activity is that they are related to growth factor receptors. The growth factor receptor is a cell surface protein. When combined with the growth factor ligand, the growth factor receptor is converted into an active form, with the protein on the inner surface of the cell membrane; This leads to phosphorylation on tyrosine residues of receptors and other proteins, and a compound with a plurality of cytoplasmic signal molecules is formed in the cells, which in turn affect many kinds of cells, such as cell division (proliferation), cell differentiation, cell growth、代谢作用对胞外微环境的表达等。更完全的讨论请参阅Schlessinger和Ullrich, Neuron, 9: 303- 391(1992), 该文包括所有附图都象本申请中充分陈述的一样, 被引用作为参考。

具有PTK活性的生长因子受体被称作受体酪氨酸激酶("RTK")。它们包含一大族具有不同生物活性的跨膜受体。目前, 已经确定了至少19种不同的RTK亚族。一个实例是称作"HER"RTK的亚族, 它包括EGFR(上皮生长因子受体)、HER2、HER3和HER4。这些RTK 组成一个胞外糖基化配体结合域、一个跨膜域和一个胞内胞质催化域, 它可将蛋白质上的酪氨酸残基磷酸化。


另一个RTK亚族包括胰岛素受体(IR)、胰岛素样生长因子受体(IGF-1R)和与胰岛素受体有关的受体(IRR)。IR和IGF-1R 与胰岛素、IGF-1和IGF-II相互作用, 形成由两个完全胞外糖基化的α亚基和两个穿过细胞膜并包含酪氨酸激酶域的β亚基构成的异四聚体。

第三个RTK亚族被称作血小板源性生长因子受体("PDGFR") 组, 其中包括PDGFRα、PDGFRβ、CSFIR、c-kit和c-fms。这些受体由含数目不定的

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters.

权利要求书

1. 式(I)化合物或其可药用的盐:



其中:

R¹选自氢, 烷基和-C(O)NR⁸R⁹;

R²选自氢, 卤素, 烷氧基, 氨基, 芳基和-S(O)₂NR¹³R¹⁴;

R³选自氢, 烷氧基, -(CO)R¹⁵, 芳基, 杂芳基和-S(O)₂NR¹³R¹⁴;

R⁴选自氢;

R⁵选自氢和烷基;

R⁶是-C(O)R¹⁰;

R⁷选自氢, 烷基和芳基;

R⁸和R⁹独立地选自氢和芳基;

R¹⁰选自氢, 烷基和芳基;

R¹¹选自氢, 烷基和芳基;

R¹²选自氢, 烷基和芳基;

R¹³选自氢, 烷基和芳基;

R¹⁴选自氢, 烷基和芳基;

R¹⁵选自氢, 烷基和芳基;

Alexandros Kanellopoulos | Manager | Log out | Terms of use | Contact us

PAT-INFORMED

Powered by WIPO

Search pharmaceutical patents by INN - Ix - tenofair

Country

INN	Participant	Patents
Sunitinib Malate		<p>CRYSTALS INCLUDING A MALIC ACID SALT OF N-[2-(DIETHYLAMINO)ETHYL]-5,5-FLUORO-2-OXO-3H-INDOLE-3-YLIDENE) METHYL-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYAMIDE, PROCESSES FOR ITS</p> <p>PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS</p>

[Contact Pfizer about this patent](#)

[Contact Pfizer about this patent](#)

PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

Participant:

The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I), and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Information on the company's policy that may be related to the product:

PHILIPPS PATENTINFORMED is not intended as a replacement for a pharmacist's expertise. It is not free of errors, and should not be relied upon as a comprehensive inventory of patent information. Patent applications are pending and in contact with patenting arrangements may prevent participation in being aware. Use of PHILIPPS PATENTINFORMED is subject to the [Terms of Use](#) and [Privacy Policy](#).

<p>Jurisdiction: WC - World</p> <p>Publication number: 11100014</p> <p>Publication date: 2001/06/21 (17 years ago)</p> <p>Filing date: 2001/02/18 (18 years ago)</p> <p>Grant number: PATENTSCOPE</p>	<p>Jurisdiction: EP - European Patent Office</p> <p>Publication number: 1204762</p> <p>Publication date: 2002/11/20 (16 years ago)</p> <p>Filing date: 2001/02/18 (18 years ago)</p> <p>Grant date: 2001/08/08 (17 years ago)</p> <p>Grant number: 1204762</p> <p>View on PATENTSCOPE</p>
<p>Jurisdiction: JP - Japan</p> <p>Filing date: 2001/06/26 (17 years ago)</p> <p>Grant date: 2001/09/12 (18 years ago)</p> <p>Grant number: A302200000</p> <p>(Country not covered by PATENTSCOPE)</p>	<p>Jurisdiction: NL - Athens</p> <p>Publication number: 1258742</p> <p>Publication date: 2002/11/20 (16 years ago)</p> <p>Filing date: 2001/02/18 (18 years ago)</p> <p>Grant date: 2001/08/08 (17 years ago)</p> <p>Grant number: 1258742</p> <p>(Country not covered by PATENTSCOPE)</p>
<p>Jurisdiction: BR - Brasilia</p> <p>Filing date: 2001/02/18 (18 years ago)</p> <p>Grant date: 2001/02/18 (18 years ago)</p> <p>Grant number: 000000</p> <p>(Country not covered by PATENTSCOPE)</p>	<p>Jurisdiction: AR - Argentina</p> <p>Filing date: 2001/02/18 (18 years ago)</p> <p>Grant date: 2001/02/27 (18 years ago)</p> <p>Grant number: 000000</p> <p>View on PATENTSCOPE</p>

Alexandros Kanellopoulos | Manager | Log out | Terms of use | Contact us

PAT-INFORMED

Patent information platform for MedTech

WIPO

Search pharmaceutical patents by INN - Ex: simvastatin

Country

INN	Participant	Product
Sumatriptan Malate		CRYSTALS INCLUDING 2-ETHYL-5-HYDROXY-2-DIMETHYL-3H-PYRRO... PYRROLE SUBSTITUTED

Contact Pfizer about this patent

From: alexandros.kanellopoulos@wipo.int

Information request:

Dear Pfizer,

I am interested in getting more information about this patent.

Thanks,

Tom

Does the enquiry relate to: a procurement intention a general query

[Send](#)

INDOLINONE PROTEIN KINASE INHIBITORS

[Contact Pfizer about this patent](#)

substituted 2-indolinone compounds of formula (I), and their...
modulate the activity of protein kinases and therefore are expected to be...
protein kinase related ocular disorders such as cancer.

[View related to the product](#)

This a database to provide accurate, timely free of errors, and should not be relied upon as a...
statements are not made, and in certain cases licensing arrangements may prevent participants from...
making statements.


Jurisdiction	EP - European Patent Office
Publication number	1231752
Publication date	2002.12.12 (18 years ago)
Filing date	2001.02.15 (18 years ago)
Grant date	2007.08.08 (12 years ago)
Grant number	1231752
View in PATENTSCOPE	
Jurisdiction	RU - Russia
Publication number	1231752
Publication date	2002.12.12 (18 years ago)
Filing date	2001.02.15 (18 years ago)
Grant date	2007.08.08 (12 years ago)
Grant number	2743
<small>(Country not covered by PATENTSCOPE.)</small>	
Jurisdiction	AR - Argentina
Filing date	2001.02.15 (18 years ago)
Grant date	2008.08.28 (13 years ago)
Grant number	22896
<small>(Country not covered by PATENTSCOPE.)</small>	
Jurisdiction	AR - Argentina
Filing date	2001.02.15 (18 years ago)
Grant date	2008.02.27 (12 years ago)
Grant number	AR0011881
View in PATENTSCOPE	

Pat-INFORMED limitations

While Pat-INFORMED can be an important tool in informing procurement, it has limitations

No Freedom to Operate

Pat-INFORMED does not provide freedom to operate and is not part of a regulated “linkage” system.



Not Error-Free

It is a database for general information purposes and is not free of errors.

Public Information

All information, including the advice received in the follow-on enquiry facility, is non-confidential. Agencies are free to challenge the information and/or seek new advice.

A living database, with room for improvement

Honest feedback encouraged

- “Report Inaccuracies” tool implemented to improve data quality.
- Changes to the landing page and disclaimers to improve clarity that the data comes directly from the companies.





On the pipeline

- Improved links with Patentscope, specially for regional patents offices

MedsPaL – Another important sources of patent information

www.medspal.org

Country	Product Name(s)	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 Afghanistan	Abacavir 300 mg	Abacavir compound	Not Filed		
	Licence(s): Bilateral licences for Sub-Saharan Africa, low-income countries and Least Developed Countries				
 Afghanistan	Abacavir 20 mg/ml Abacavir 60 mg	Abacavir compound	Not Filed		
	Licence(s): Bilateral licences for Sub-Saharan Africa, low-income countries and Least Developed Countries MPP licence on paediatric formulations of abacavir (ABC)				

WIPO FOR OFFICIAL USE ONLY

Thank you

For further information contact:

Guilherme Cintra

- +41 22 338 32 22
- g.cintra@ifpma.org

